What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Salomé Adeyemi
Page 2 of 13 of this archive, newest first.
Archive — page 2
243 piecesDual, triple, co-formulated: a taxonomy the coverage keeps collapsing
A dual agonist is one molecule with two receptor activities. A co-formulation is two molecules in one pen. The coverage treats them as synonyms.
Nought point nine eight of a dalton: the modification that hides in plain sight
What would be needed to catch each of these, and what it would cost.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Why VendorInvestigate can tell you the mass is right and not that the sequence is
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
One receptor, several signals: the case for reading liraglutide as a biased agonist
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
One receptor, several signals: the case for reading semaglutide as a biased agonist
A tour of what happens in the thirty seconds after binding, and why it matters at week thirty.
Dose-limiting: a definition worth being strict about
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The limits of mechanism: why receptor data will not tell you who responds
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Target dose, effective dose, and the distance between them
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
A percentage is not a specification
This piece takes the measurement apart into the decisions it is made of, because each decision moves the answer.
The brainstem does most of the work
A tour of the tissues where the receptor is expressed, and what happens in each.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.